What does a GMP compliance consultant do for small biotech or medical device startups?
A GMP compliance consultant helps early-stage biotech and medical device companies interpret FDA 21 CFR and ISO requirements, build scalable quality systems, prepare for inspections, and fix gaps before they lead to 483s or Warning Letters. For startups entering Phase 2/3 or preparing for commercial launch, this often includes validation, SOP development, equipment qualification, and general GMP readiness.
How can I prepare for an FDA inspection if my company has never been audited before?
Preparing for your first FDA inspection involves creating a realistic audit-readiness plan, performing a gap assessment against current FDA expectations, and training your team on inspection behavior. A consultant can run a mock FDA audit, identify high-risk issues, and help remediate problems quickly so you’re inspection-ready.
What is the fastest way to fix GMP compliance gaps after receiving an FDA 483 or Warning Letter?
Before the inspection, a gap analysis can be performed to identify and address vulnerabilities. The fastest and most effective way to fix GMP compliance gaps after receiving an FDA Form 483 or Warning Letter is to perform a root cause analysis, prioritize high-risk findings, and create a corrective and preventive action (CAPA) plan that meets FDA expectations. A consultant experienced in “rapid remediation” for 483s can help you respond within deadlines and avoid escalation.
How do I know which systems or equipment need validation in a GMP-regulated environment?
Equipment and systems require validation if they impact product quality, data integrity, or GMP decision-making. A consultant can perform a risk-based validation assessment to determine which instruments, software, and utilities need IQ/OQ/PQ or re-qualification according to FDA and EU Annex 11 guidelines.
What should I do if I discover validation or compliance gaps shortly before an FDA inspection?
Prioritize the gaps based on regulatory and operational risk rather than trying to fix everything at once. Address issues that could affect product quality, patient safety, data integrity, or the ability to demonstrate control. Where a gap cannot reasonably be corrected before the inspection, establish a documented remediation plan with clear actions, responsibilities, and timing.
What are the most common FDA GMP observations, and can I fix them before the inspector leaves?
- The most common FDA GMP observations (listed on Form 483s across biotech, pharmaceutical, and medical device companies) typically include:
- Inadequate or missing SOPs
- Poor documentation practices (data integrity issues)
- Incomplete or missing equipment validation/qualification
- Failure to follow established procedures
- Inadequate CAPA investigations or root cause analysis
- Insufficient training or training records
- Uncontrolled change management or configuration control
- Environmental monitoring or calibration gaps
Of course it is better not to have any observations, but it is sometimes possible to address potential observations while the inspector is still on site. Consultants can help with preparation and remediation if internal resources are stretched.
When should I bring in an independent GMP compliance or validation consultant?
Independent support can be useful when preparing for an inspection, responding to an audit finding, evaluating validation or compliance gaps, or when internal resources are limited. An outside review can also help determine whether an existing approach is appropriate before committing significant time and resources to remediation or validation work.